Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Aragen will deploy its proven experimental integrated drug discovery (IDD) platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: FAR Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 30, 2023
Details:
In accordance with the agreement, Aragen will do a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 26, 2021
Details:
Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.
Lead Product(s): Xentuzumab,Everolimus,Exemestane
Therapeutic Area: Oncology Product Name: BI 836845
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2021
Details:
The aim of this partnership is to identify the uPRIT with the optimal urokinase plasminogen activator receptor binding profile, enabling selective delivery of a cytotoxic radioisotope to just those aberrantly activated immune cells that produce the cytokine storm.
Lead Product(s): MNPR-101
Therapeutic Area: Infections and Infectious Diseases Product Name: MNPR-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Monopar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 19, 2020
Details:
Under the terms of the collaboration, Aragen is set to provide Serum with high expressing cell lines enabling Serum to quickly move their RapTr™ platform forward into Manufacturing.
Lead Product(s): CHO-DG44
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Serum Institute of India Private Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2020